Objective: To compare the surgical outcomes and clinical improvement 1 year after laparoscopic partial and total adrenalectomy for the treatment of patients with nonhereditary unilateral functional adrenal adenomas. Material and Methods: From March 2016 to January 2018, we performed 15 laparoscopic partial adrenalectomy (LPA; Group 1) and 25 laparoscopic total adrenalectomy (LTA; Group 2) procedures. The key points reside in adenoma identification, preservation of the remaining glandular parenchyma, and its blood supply with dissection in the space between the adenoma and the normal parenchyma. The operative and clinical outcomes were compered. Results: The mean age of the patients was 45.1 (17–69) years and the median follow-up was 15 (12–26) months. Operative time, blood loss, and hospital stay were similar between the groups. No major perioperative and postoperative complications occurred. After surgery, all patients had resolution of their symptoms, with no patient in Group 1 requiring steroid replacement. However, a patient in Group 2 required steroid replacement therapy. On postoperative imaging, no residual and recurrent mass was detected. Conclusions: Our results showed that LPA is safe and feasible, and has similar therapeutic results compared with LTA in patients with a nonhereditary hormonally active unilateral adrenal mass. Furthermore, LPA can obviate the need for steroid replacement in these patients.

Keywords:
Adrenalectomy, Partial, Total, Laparoscopy
1.
Gagner M, Lacroix A, Bolté E. Laparoscopic adrenalectomy in Cushing’s syndrome and pheochromocytoma.
N Engl J Med
. 1992 Oct;327(14):1033.
2.
Gagner M, Pomp A, Heniford BT, Pharand D, Lacroix A. Laparoscopic adrenalectomy: lessons learned from 100 consecutive procedures.
Ann Surg
. 1997 Sep;226(3):238–46.
3.
Brunt LM, Doherty GM, Norton JA, Soper NJ, Quasebarth MA, Moley JF. Laparoscopic adrenalectomy compared to open adrenalectomy for benign adrenal neoplasms.
J Am Coll Surg
. 1996 Jul;183(1):1–10.
4.
Diner EK, Franks ME, Behari A, Linehan WM, Walther MM. Partial adrenalectomy: the National Cancer Institute experience.
Urology
. 2005 Jul;66(1):19–23.
5.
Lairmore TC, Ball DW, Baylin SB, Wells SA Jr. Management of pheochromocytomas in patients with multiple endocrine neoplasia type 2 syndromes.
Ann Surg
. 1993 Jun;217(6):595–601.
6.
Manny TB, Pompeo AS, Hemal AK. Robotic partial adrenalectomy using indocyanine green dye with near-infrared imaging: the initial clinical experience.
Urology
. 2013 Sep;82(3):738–42.
7.
Mantero F, Terzolo M, Arnaldi G, Osella G, Masini AM, Alì A, et al. A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology.
J Clin Endocrinol Metab
. 2000 Feb;85(2):637–44.
8.
Chen SF, Chueh SC, Wang SM, Wu VC, Pu YS, Wu KD, et al. Clinical outcomes in patients undergoing laparoscopic adrenalectomy for unilateral aldosterone producing adenoma: partial versus total adrenalectomy.
J Endourol
. 2014 Sep;28(9):1103–6.
9.
Boris RS, Gupta G, Linehan WM, Pinto PA, Bratslavsky G. Robot-assisted laparoscopic partial adrenalectomy: initial experience.
Urology
. 2011 Apr;77(4):775–80.
10.
Nakada T, Kubota Y, Sasagawa I, Yagisawa T, Watanabe M, Ishigooka M. Therapeutic outcome of primary aldosteronism: adrenalectomy versus enucleation of aldosterone-producing adenoma.
J Urol
. 1995 Jun;153(6):1775–80.
11.
Kaye DR, Storey BB, Pacak K, Pinto PA, Linehan WM, Bratslavsky G. Partial adrenalectomy: underused first line therapy for small adrenal tumors.
J Urol
. 2010 Jul;184(1):18–25.
12.
Fu B, Zhang X, Wang GX, Lang B, Ma X, Li HZ, et al. Long-term results of a prospective, randomized trial comparing retroperitoneoscopic partial versus total adrenalectomy for aldosterone producing adenoma.
J Urol
. 2011 May;185(5):1578–82.
13.
Ishidoya S, Ito A, Sakai K, Satoh M, Chiba Y, Sato F, et al. Laparoscopic partial versus total adrenalectomy for aldosterone producing adenoma.
J Urol
. 2005 Jul;174(1):40–3.
14.
Nagaraja V, Eslick GD, Edirimanne S. Recurrence and functional outcomes of partial adrenalectomy: a systematic review and meta-analysis.
Int J Surg
. 2015 Apr;16 Pt A:7–13.
15.
Miron A, Giulea C, Nădrăgea M, Enciu O; -. Laparoscopic Partial Adrenalectomy.
Chirurgia (Bucur)
. 2017 Jan-Feb;112(1):77–81.
16.
Colleselli D, Janetschek G. Current trends in partial adrenalectomy.
Curr Opin Urol
. 2015 Mar;25(2):89–94.
17.
Roukounakis N, Dimas S, Kafetzis I, Bethanis S, Gatsulis N, Kostas H, et al. Is preservation of the adrenal vein mandatory in laparoscopic adrenal-sparing surgery?
JSLS
. 2007 Apr-Jun;11(2):215–8.
18.
Ikeda Y, Takami H, Niimi M, Kan S, Sasaki Y, Takayama J. Laparoscopic partial or cortical-sparing adrenalectomy by dividing the adrenal central vein.
Surg Endosc
. 2001 Jul;15(7):747–50.
19.
Edström E, Gröndal S, Norström F, Palmér M, Svensson KA, Widell H, et al. Long term experience after subtotal adrenalectomy for multiple endocrine neoplasia type IIa.
Eur J Surg
. 1999 May;165(5):431–5.
20.
Brauckhoff M, Gimm O, Thanh PN, Bär A, Ukkat J, Brauckhoff K, et al. Critical size of residual adrenal tissue and recovery from impaired early postoperative adrenocortical function after subtotal bilateral adrenalectomy.
Surgery
. 2003 Dec;134(6):1020–7.
© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.